Loading…
Loading…
OLK (Olink Holding AB (publ)) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference, not a current-day signal.
OLK does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for OLK and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Value Graph.
TapClick below to see what's inside, then upgrade to unlock for OLK and 80,000+ other tickers.
See exactly how OLK's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OLK and 80,000+ other tickers.
Olink Holding AB (publ) offers a comprehensive suite of products and services tailored for life science research institutions, including academic bodies, government entities, biopharmaceutical companies, and biotechnology firms. The company's product lines include Olink Explore, which is designed to aid research in critical areas such as cardiovascular and metabolic health, oncology, neurology, and inflammation. Additionally, it features the Olink Target product line and the Olink Focus product line, the latter providing bespoke solutions for clients who have already pinpointed specific…
Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. The certification, part of Thermo Fisher's Life Sciences Solutions network, enables Verici Dx to support biomarker discovery, algorithm development, validation, clinical trials and diagnostic applications for both external clients and its own development pipeline.
UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the introduction of Olink® Reveal, setting a new standard for affordable, high-plex proteomics that enables researchers to identify circulating biomarkers for a range of applications with reduced cost and set up requirements. Olink Reveal represents a powerful new tool for proteomics research, measuring ~1,000 carefully selected human proteins to broadly screen the proteome while als.
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.
Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.
UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced tender offer (the “Offer”) by Orion Acquisition AB (the “Buyer”), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher” or “Parent”), for all outstanding Common Shares and American Depositary Shares (together, the “Shares”) of Olink for $26.00 per Share.